

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2022 October 15; 14(10): 1892-2087



**MINIREVIEWS**

- 1892 Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers  
*Shan DD, Zheng QX, Chen Z*
- 1903 Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis  
*Zhang HQ, Li J, Tan CL, Chen YH, Zheng ZJ, Liu XB*

**ORIGINAL ARTICLE****Basic Study**

- 1918 Transcriptional factor III A promotes colorectal cancer progression by upregulating cystatin A  
*Wang J, Tan Y, Jia QY, Tang FQ*
- 1933 VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors  
*Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL*
- 1949 Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer  
*Feng ML, Wu C, Zhang HJ, Zhou H, Jiao TW, Liu MY, Sun MJ*
- 1968 Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells  
*Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX*
- 1981 Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma  
*Huang EM, Ma N, Ma T, Zhou JY, Yang WS, Liu CX, Hou ZH, Chen S, Zong Z, Zeng B, Li YR, Zhou TC*

**Retrospective Study**

- 2004 Multi-slice spiral computed tomography in differential diagnosis of gastric stromal tumors and benign gastric polyps, and gastric stromal tumor risk stratification assessment  
*Li XL, Han PF, Wang W, Shao LW, Wang YW*
- 2014 Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy  
*Zhao JY, Tang QQ, Luo YT, Wang SM, Zhu XR, Wang XY*

**Observational Study**

- 2025 Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer  
*Pacheco-Barcia V, Gomez D, Obispo B, Mihic Gongora L, Hernandez San Gil R, Cruz-Castellanos P, Gil-Raga M, Villalba V, Ghanem I, Jimenez-Fonseca P, Calderon C*

- 2038 Droplet digital polymerase chain reaction assay for methylated ring finger protein 180 in gastric cancer

*Guo GH, Xie YB, Jiang T, An Y*

**Prospective Study**

- 2048 Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study

*Chen N, Li CL, Peng YF, Yao YF*

**META-ANALYSIS**

- 2061 Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis

*Bai XS, Zhou SN, Jin YQ, He XD*

**CASE REPORT**

- 2077 Disseminated carcinomatosis of the bone marrow caused by granulocyte colony-stimulating factor: A case report and review of literature

*Fujita K, Okubo A, Nakamura T, Takeuchi N*

**CORRECTION**

- 2085 Correction to "Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 $\alpha$ -induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis"

*Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ*

**ABOUT COVER**

Editorial Board of *World Journal of Gastrointestinal Oncology*, Sezer Saglam, MD, Full Professor, Medical Oncology, Demiroglu Bilim University, Istanbul 34349, Turkey. [saglam@istanbul.edu.tr](mailto:saglam@istanbul.edu.tr)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (*WJGO*, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJGO* mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJGO* as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The *WJGO*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

October 15, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis”

Bu-Wei Teng, Kun-Dong Zhang, Yu-Han Yang, Zeng-Ya Guo, Wei-Wei Chen, Zheng-Jun Qiu

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu H, United States; Solimando AG, Italy; Trna J, Czech Republic

**Received:** April 6, 2022

**Peer-review started:** April 6, 2022

**First decision:** June 12, 2022

**Revised:** June 15, 2022

**Accepted:** September 13, 2022

**Article in press:** September 13, 2022

**Published online:** October 15, 2022



**Bu-Wei Teng**, Department of General Surgery, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China

**Bu-Wei Teng**, Department of General Surgery, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang, Lianyungang 222061, Jiangsu Province, China

**Kun-Dong Zhang, Yu-Han Yang, Zeng-Ya Guo, Wei-Wei Chen, Zheng-Jun Qiu**, Department of General Surgery, Shanghai General Hospital, Shanghai 200080, China

**Corresponding author:** Zheng-Jun Qiu, MD, Chief Doctor, Director, Surgeon, Department of General Surgery, Shanghai General Hospital, No. 100 Haining Road, Shanghai 200080, China. [zhengjun.qiu@shgh.cn](mailto:zhengjun.qiu@shgh.cn)

### Abstract

Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis” (PMID: 34853645 PMID: PMC8603463 DOI: 10.4251/wjgo.v13.i11.1709). In this article, the picture of Figure 6C was misused due to our carelessness while typesetting. We corrected this mistake, and replaced the incorrect image with the correct one.

**Key Words:** Correction; Error; Figure; CRISPR-Cas9

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis.”

**Citation:** Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ. Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 $\alpha$ -induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis”. *World J Gastrointest Oncol* 2022; 14(10): 2085-2087

**URL:** <https://www.wjgnet.com/1948-5204/full/v14/i10/2085.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v14.i10.2085>

## TO THE EDITOR

After confirming the figures in our manuscript, we were surprised to find a mistake in Figure 6C[1]. It was an unintentional error that occurred when we typeset the images. We have replaced the incorrect images with the correct Figure 6C (Figure 1). Figure 6D-E was based on the correct image and does not need to be changed. We assure you that this mistake does not change the meaning of the picture or the conclusion of the manuscript. We apologize for our careless mistake, which has caused great inconvenience.



**Figure 1** We replaced the incorrect images with the correct Figure 6C in “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 $\alpha$ -induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis.”

## FOOTNOTES

**Author contributions:** Teng BW found and corrected the misused figure; Zhang KD, Yang YH, Guo ZY, Chen WW, and Qiu ZJ checked the correction.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Bu-Wei Teng 0000-0002-9555-2830; Kun-Dong Zhang 0000-0002-2232-2153; Yu-Han Yang 0000-0002-3717-5088; Zeng-Ya Guo 0000-0001-8310-5147; Wei-Wei Chen 0000-0001-8325-5663; Zheng-Jun Qiu 0000-0002-8318-847X.

**S-Editor:** Chen YL

**L-Editor:** Filipodia

**P-Editor:** Chen YL

---

## REFERENCES

---

- 1 **Teng BW**, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ. Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 $\alpha$ -induced *CBX8* transcription promotes pancreatic cancer progression via IRS1/AKT axis. *World J Gastrointest Oncol* 2021; **13**: 1709-1724 [PMID: 34853645 DOI: 10.4251/wjgo.v13.i11.1709]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

